About
Company Management
Board of Directors
Scientific Advisory Board
Timeline
Careers
Technology
Oncoprex Immunogene Therapy
Nanovesicle Delivery
Clinical Trials
Pipeline
Oncoprex Monotherapy
Erlotinib Combination
Investors
Overview
Company Profile
Stock Information
SEC Filings
Analyst Coverage
Corporate Governance
Shareholder FAQ
Downloads
News
Press Releases
Media Coverage
Events
Videos
Email Alerts
Contact
About
Company Management
Board of Directors
Scientific Advisory Board
Timeline
Careers
Technology
Oncoprex Immunogene Therapy
Nanovesicle Delivery
Clinical Trials
Pipeline
Oncoprex Monotherapy
Erlotinib Combination
Investors
Overview
Company Profile
Stock Information
SEC Filings
Analyst Coverage
Corporate Governance
Shareholder FAQ
Downloads
News
Press Releases
Media Coverage
Events
Videos
Email Alerts
Contact
© 2019 Genprex Inc. All Rights Reserved.
Monthly Archives:
May 2010
SPORE Grants Turn Into Hope for Patients
May 4, 2010
SPORE Grants Turn Into Hope for Patients
Read More
Search for:
Categories
Conferences
Education
Industry News
Media Coverage
Press Releases
Recent Posts
Genprex is Defining a New Immunogene Therapy that Could Change the Course of Cancer
Independent Researchers Find Genprex’s TUSC2 Prevents Tumor Growth in Triple-Negative Breast Cancer
Genprex to Present at the H.C. Wainwright 21st Annual Global Investment Conference
Genprex Provides Forward Looking Guidance and Updates on Corporate Activities, Publishes New Corporate Deck
Pfizer’s Half-Billion-Dollar Manufacturing Facility Demonstrates Commitment to Gene Therapy
Archives
September 2019
August 2019
July 2019
May 2019
April 2019
March 2019
February 2019
January 2019
December 2018
November 2018
October 2018
September 2018
August 2018
July 2018
June 2018
May 2018
April 2018
March 2018
October 2017
July 2017
April 2017
March 2017
January 2017
December 2016
November 2016
August 2016
May 2014
April 2012
September 2011
July 2011
June 2011
April 2011
May 2010
